TARS Tarsus Pharmaceuticals Forecast, Technical & Fundamental Analysis
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care... Show more
TARS is expected to report earnings to rise 260.47% to -154 cents per share on November 10
Q3'26
Est.
$-1.55
Q2'26
Missed
by $0.21
Q1'26
Beat
by $0.14
Q4'25
Missed
by $0.12
Q3'25
Beat
by $0.05
The last earnings report on August 06 showed earnings per share of -43 cents, missing the estimate of -21 cents. With 330.11K shares outstanding, the current market capitalization sits at 3.19B.
A.I.dvisor indicates that over the last year, TARS has been loosely correlated with GMAB. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if TARS jumps, then GMAB could also see price increases.
TARS in -2.66% downward trend, sliding for three consecutive days on July 29, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TARS declined for three days, in of 301 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
TARS broke above its upper Bollinger Band on August 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on TARS as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TARS just turned positive on July 30, 2026. Looking at past instances where TARS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
TARS moved above its 50-day moving average on August 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TARS crossed bullishly above the 50-day moving average on August 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TARS advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 239 cases where TARS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TARS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.200) is normal, around the industry mean (20.145). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.149) is also within normal values, averaging (444.692).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
